<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>气（粉）雾剂 &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/qifenwuji/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Fri, 18 Jun 2021 06:14:25 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>气（粉）雾剂 &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>CRI元哲：2021-2025年中国布地奈德福莫特罗市场研究报告(中文版含税价人民币12,000元)</title>
		<link>https://www.yuanzhezixun.com/2021-2025nianzhongguobudenaidefumoteluoshichangyanjiubaogao/</link>
		
		<dc:creator><![CDATA[Timlee]]></dc:creator>
		<pubDate>Tue, 11 May 2021 07:43:34 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[COPD]]></category>
		<category><![CDATA[SYMBICORT]]></category>
		<category><![CDATA[信必可]]></category>
		<category><![CDATA[哮喘]]></category>
		<category><![CDATA[哮喘及慢性阻塞性肺病]]></category>
		<category><![CDATA[复方制剂]]></category>
		<category><![CDATA[布地奈德]]></category>
		<category><![CDATA[布地奈德福莫特罗]]></category>
		<category><![CDATA[气（粉）雾剂]]></category>
		<category><![CDATA[福莫特罗]]></category>
		<category><![CDATA[阿斯利康]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=24017</guid>

					<description><![CDATA[CRI元哲的调研数据显示，2016-2019年，布地奈德福莫特罗在中国市场的销售额总体呈上升趋势。而2020年的年销售额约为大约为四亿元，相较于2019年减少了15.6%。主要原因是COVID-19疫情使中国医院整体诊疗业务受到冲击。中国市场布地奈德福莫特罗销售额在2016-2020的CAGR为3.3%。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
